Eliprodil
Exploratory indications: neuropathic pain, post-stroke neuroprotection
- CAS No.
- 119431-25-3
- Indication Class
- CNS / Psychiatry
- Patent Expiry
- Off-patent · 2020 (to verify)
- Therapeutic Area
- Neurology
- Labeled Purity
- 99%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- Confirm per inquiry
- Patent Scope
- 1990s compound patent; expired per 20-yr term estimate — to be verified
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
A selective NR2B-subtype antagonist with fewer psychotropic side effects than traditional NMDA antagonists, a common tool compound for neuroscience research.
Neurology · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Eliprodil is an investigational drug that acts as a selective antagonist of the NMDA receptor, specifically targeting its NR2B subunit. This mechanism is designed to modulate glutamate signaling in the brain. It has been evaluated in clinical trials for its potential to treat Parkinson's disease and related movement disorders.
Supply source: Unibest · Eliprodil, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.